Advice
following a full submission:
empagliflozin (Jardiance®) is accepted for use within NHSScotland.
Indication under review: in adults for the treatment of symptomatic chronic heart failure with preserved ejection fraction (left ventricular ejection fraction [LVEF] >40%).
In a phase III study of adults with symptomatic chronic heart failure and LVEF >40%, the addition of empagliflozin to standard of care significantly improved time to first hospitalisation for heart failure or cardiovascular death.
SMC has issued separate advice for empagliflozin in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction (SMC2396).
Download detailed advice773KB (PDF)
Medicine details
- Medicine name:
- empagliflozin (Jardiance)
- SMC ID:
- SMC2523
- Indication:
For chronic HF patients with LVEF >40% to cover the entire spectrum of the HF population.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 May 2023